Trial · NCT04020016
Results by group80
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 80
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Part 1: Maximum Observed Plasma Concentration (Cmax) of NAL ER | Cohort 1: NAL ER 27 mg | Mild Hepatic Impairment (Group 1) | 3.30 | Geometric Coefficient of Variation 41.8 | nanogram per milliliter (ng/mL) |
| Part 1: Maximum Observed Plasma Concentration (Cmax) of NAL ER | Cohort 2: NAL ER 54 mg | Mild Hepatic Impairment (Group 1) | 7.67 | Geometric Coefficient of Variation 38.9 | nanogram per milliliter (ng/mL) |
| Part 1: Maximum Observed Plasma Concentration (Cmax) of NAL ER | Cohort 3: NAL ER 108 mg | Mild Hepatic Impairment (Group 1) | 13.9 | Geometric Coefficient of Variation 34.1 | nanogram per milliliter (ng/mL) |
| Part 1: Maximum Observed Plasma Concentration (Cmax) of NAL ER | Cohort 4: NAL ER 162 mg | Mild Hepatic Impairment (Group 1) | 18.7 | Geometric Coefficient of Variation 34.9 | nanogram per milliliter (ng/mL) |
| Part 1: Maximum Observed Plasma Concentration (Cmax) of NAL ER | Cohort 1: NAL ER 27 mg | Moderate Hepatic Impairment (Group 2) | 10.9 | Geometric Coefficient of Variation 77.9 | nanogram per milliliter (ng/mL) |
| Part 1: Maximum Observed Plasma Concentration (Cmax) of NAL ER | Cohort 2: NAL ER 54 mg | Moderate Hepatic Impairment (Group 2) | 22.3 | Geometric Coefficient of Variation 70.7 | nanogram per milliliter (ng/mL) |
| Part 1: Maximum Observed Plasma Concentration (Cmax) of NAL ER | Cohort 3: NAL ER 108 mg | Moderate Hepatic Impairment (Group 2) | 42.4 | Geometric Coefficient of Variation 52.2 | nanogram per milliliter (ng/mL) |
| Part 1: Maximum Observed Plasma Concentration (Cmax) of NAL ER | Cohort 4: NAL ER 162 mg | Moderate Hepatic Impairment (Group 2) | 57.2 | Geometric Coefficient of Variation 55.3 | nanogram per milliliter (ng/mL) |
| Part 1: Maximum Observed Plasma Concentration (Cmax) of NAL ER | Cohort 1: NAL ER 27 mg | Severe Hepatic Impairment (Group 3) | 27.7 | Geometric Coefficient of Variation 21.9 | nanogram per milliliter (ng/mL) |
| Part 1: Maximum Observed Plasma Concentration (Cmax) of NAL ER | Cohort 5: NAL ER 162 mg | No Hepatic Impairment (Group 4) | 25.7 | Geometric Coefficient of Variation 34.2 | nanogram per milliliter (ng/mL) |
| Part 1: Time to Reach Maximum Observed Plasma Concentration (Tmax) of NAL ER | Cohort 1: NAL ER 27 mg | Mild Hepatic Impairment (Group 1) | 4.000 | Full Range 1.500 to 7.000 | hours (h) |
| Part 1: Time to Reach Maximum Observed Plasma Concentration (Tmax) of NAL ER | Cohort 2: NAL ER 54 mg | Mild Hepatic Impairment (Group 1) | 5.000 | Full Range 3.000 to 12.000 | hours (h) |
| Part 1: Time to Reach Maximum Observed Plasma Concentration (Tmax) of NAL ER | Cohort 3: NAL ER 108 mg | Mild Hepatic Impairment (Group 1) | 5.000 | Full Range 1.500 to 12000 | hours (h) |
| Part 1: Time to Reach Maximum Observed Plasma Concentration (Tmax) of NAL ER | Cohort 4: NAL ER 162 mg | Mild Hepatic Impairment (Group 1) | 7.000 | Full Range 3.000 to 24.000 | hours (h) |
| Part 1: Time to Reach Maximum Observed Plasma Concentration (Tmax) of NAL ER | Cohort 1: NAL ER 27 mg | Moderate Hepatic Impairment (Group 2) | 3.000 | Full Range 3.000 to 9.000 | hours (h) |
| Part 1: Time to Reach Maximum Observed Plasma Concentration (Tmax) of NAL ER | Cohort 2: NAL ER 54 mg | Moderate Hepatic Impairment (Group 2) | 5.000 | Full Range 3.000 to 12.067 | hours (h) |
| Part 1: Time to Reach Maximum Observed Plasma Concentration (Tmax) of NAL ER | Cohort 3: NAL ER 108 mg | Moderate Hepatic Impairment (Group 2) | 9.000 | Full Range 3.000 to 12.000 | hours (h) |
| Part 1: Time to Reach Maximum Observed Plasma Concentration (Tmax) of NAL ER | Cohort 4: NAL ER 162 mg | Moderate Hepatic Impairment (Group 2) | 7.000 | Full Range 3.000 to 12.000 | hours (h) |
| Part 1: Time to Reach Maximum Observed Plasma Concentration (Tmax) of NAL ER | Cohort 1: NAL ER 27 mg | Severe Hepatic Impairment (Group 3) | 6.000 | Full Range 3.000 to 9.000 | hours (h) |
| Part 1: Time to Reach Maximum Observed Plasma Concentration (Tmax) of NAL ER | Cohort 5: NAL ER 162 mg | No Hepatic Impairment (Group 4) | 5.000 | Full Range 2.983 to 9.000 | hours (h) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04020016/results